Related Experiment Video
Updated: May 28, 2026
04:49
A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice
Published on: July 5, 2024
Modern Polycystic Ovary Syndrome (PCOS) Management: Intelligent Drug Delivery and Metabolic Reprogramming for Ovarian
Abdel Halim Harrath1, Maroua Jalouli2, Mohammed Al-Zharani2
1Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Biomolecules
|May 27, 2026
Summary
New therapies for polycystic ovarian syndrome (PCOS) focus on molecular targets, utilizing advanced drug delivery and AI for improved ovarian restoration and fertility outcomes. These innovative approaches aim to address the root causes of PCOS, offering long-term benefits.
Area of Science:
- Reproductive Endocrinology and Metabolism
- Nanomedicine
- Artificial Intelligence in Healthcare
Background:
- Polycystic ovarian syndrome (PCOS) is a complex endocrine and metabolic disorder impacting reproductive, metabolic, and cardiovascular health.
- Key features include hyperandrogenism, anovulation, insulin resistance, oxidative stress, and altered ovarian microenvironment.
- Current treatments offer symptomatic relief but lack disease-modifying capabilities for underlying molecular drivers of infertility.
Purpose of the Study:
- To review recent advancements in understanding PCOS pathophysiology.
- To introduce novel, next-generation therapeutics targeting molecular and cellular processes in PCOS.
- To discuss innovative strategies for ovarian restoration and fertility optimization.
Main Methods:
- Exploration of nanoparticle- and nanofiber-based drug delivery systems for targeted ovarian therapy.
- Review of metabolic reprogramming strategies addressing insulin resistance, mitochondrial dysfunction, and autophagy.
- Analysis of AI-enabled precision medicine approaches for PCOS management and fertility prediction.
Main Results:
- Nanodelivery systems enhance bioavailability and controlled release of therapeutic agents (insulin sensitizers, antioxidants, anti-androgens).
- Metabolic interventions show potential for disease modification by targeting key cellular pathways.
- AI facilitates personalized PCOS management through phenotype classification and predictive modeling.
Conclusions:
- Next-generation therapeutics offer targeted delivery and molecular-level intervention for PCOS.
- Metabolic reprogramming and AI-driven precision medicine represent promising disease-modifying strategies.
- These innovative approaches hold potential for long-term ovarian restoration and improved fertility in women with PCOS.
Related Concept Videos
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:28Infertility in Females
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of endometrial...
Endometriosis, a condition characterized by abnormal growth of endometrial...
01:27Ovarian Cycle
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:22Oogenesis
Oogenesis, the process of developing egg cells (female gametes), occurs within the ovaries and is fundamental to female fertility. This sequence begins during fetal development when diploid oogonia in the developing ovaries undergo mitotic divisions to produce primary oocytes. By birth, these primary oocytes enter prophase I of meiosis but become arrested in this stage, remaining suspended until puberty.
Each primary oocyte is surrounded by a layer of pre-granulosa cells, forming what is known...
Each primary oocyte is surrounded by a layer of pre-granulosa cells, forming what is known...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...